Regeneron’s commercial future

As its long-standing tie-up with Sanofi winds down, the main loss Regeneron faces is access to the pharma’s commercial footprint, as the biotech has yet to build one for itself.

An analysis of Regeneron’s wholly owned pipeline suggests it may be able to go it alone for about a third, while the others will likely require a partner, particularly outside the U.S. ...